Home › Rosetta Genomics Completes Private Placement Tranche

Rosetta Genomics Completes Private Placement Tranche

Feb 23, 2017

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has completed the second tranche of a previously announced $5 million placement of stock and convertible debentures.

In the new tranche, the firm sold newly registered convertible debentures, which can be converted into about 2.6 million ordinary shares, for gross proceeds of $1.3 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS Approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

What's Popular?

In Molecular Diagnostics

  1. Cancer Genetics Cancels Planned Merger With NovellusDx

  2. Black Women With Breast Cancer Fare Worse, TAILORx Analysis Confirms at SABCS

    Premium

  3. Mobidiag, Autobio Diagnostics to Form Joint Venture in China

  4. Guardant Health to Develop Blood-Based CDx for AstraZeneca Drugs

  5. Exosome Diagnostics Suing Former Employee for IP Theft

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.